| Moeed Asghar, MBBS | |
|
3366 Oakdale Ave N Ste 401, Robbinsdale, MN 55422-2986 | |
| (763) 398-6383 | |
| Not Available |
| Full Name | Moeed Asghar |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 19 Years |
| Location | 3366 Oakdale Ave N Ste 401, Robbinsdale, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215171285 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Cloud Hospital | Saint cloud, MN | Hospital |
| Mayo Clinic Health System - Mankato | Mankato, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centracare Clinic | 2466363395 | 632 |
| Mayo Clinic Health System-southwest Minnesota Region | 4688585771 | 533 |
News Archive
Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).
ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).
Macrophages are immune system cells. They are essential in the early response to infections, and they also have a key role in the proper functioning of our tissues and the regulation of obesity.
DIPG (Diffuse Intrinsic Pontine Glioma) is a rare malignant cerebral tumour in children. It has only a 1% 5-year survival rate, amongst other things because it is not possible to operate because the tumour is located in the brain stem.
› Verified 6 days ago
| Entity Name | Centracare Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043212665 PECOS PAC ID: 2466363395 Enrollment ID: O20031105000293 |
News Archive
Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).
ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).
Macrophages are immune system cells. They are essential in the early response to infections, and they also have a key role in the proper functioning of our tissues and the regulation of obesity.
DIPG (Diffuse Intrinsic Pontine Glioma) is a rare malignant cerebral tumour in children. It has only a 1% 5-year survival rate, amongst other things because it is not possible to operate because the tumour is located in the brain stem.
› Verified 6 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545422 PECOS PAC ID: 4688585771 Enrollment ID: O20031110000134 |
News Archive
Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).
ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).
Macrophages are immune system cells. They are essential in the early response to infections, and they also have a key role in the proper functioning of our tissues and the regulation of obesity.
DIPG (Diffuse Intrinsic Pontine Glioma) is a rare malignant cerebral tumour in children. It has only a 1% 5-year survival rate, amongst other things because it is not possible to operate because the tumour is located in the brain stem.
› Verified 6 days ago
| Entity Name | St Josephs Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568415974 PECOS PAC ID: 8224948443 Enrollment ID: O20031119000468 |
News Archive
Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).
ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).
Macrophages are immune system cells. They are essential in the early response to infections, and they also have a key role in the proper functioning of our tissues and the regulation of obesity.
DIPG (Diffuse Intrinsic Pontine Glioma) is a rare malignant cerebral tumour in children. It has only a 1% 5-year survival rate, amongst other things because it is not possible to operate because the tumour is located in the brain stem.
› Verified 6 days ago
| Entity Name | North Memorial Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851344907 PECOS PAC ID: 0042123028 Enrollment ID: O20040122000470 |
News Archive
Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).
ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).
Macrophages are immune system cells. They are essential in the early response to infections, and they also have a key role in the proper functioning of our tissues and the regulation of obesity.
DIPG (Diffuse Intrinsic Pontine Glioma) is a rare malignant cerebral tumour in children. It has only a 1% 5-year survival rate, amongst other things because it is not possible to operate because the tumour is located in the brain stem.
› Verified 6 days ago
| Entity Name | St Cloud Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043269798 PECOS PAC ID: 4880594779 Enrollment ID: O20110221000134 |
News Archive
Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).
ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).
Macrophages are immune system cells. They are essential in the early response to infections, and they also have a key role in the proper functioning of our tissues and the regulation of obesity.
DIPG (Diffuse Intrinsic Pontine Glioma) is a rare malignant cerebral tumour in children. It has only a 1% 5-year survival rate, amongst other things because it is not possible to operate because the tumour is located in the brain stem.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Moeed Asghar, MBBS 2800 Campus Dr Ste 10, Plymouth, MN 55441-8812 Ph: (763) 398-4400 | Moeed Asghar, MBBS 3366 Oakdale Ave N Ste 401, Robbinsdale, MN 55422-2986 Ph: (763) 398-6383 |
News Archive
Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).
ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).
Macrophages are immune system cells. They are essential in the early response to infections, and they also have a key role in the proper functioning of our tissues and the regulation of obesity.
DIPG (Diffuse Intrinsic Pontine Glioma) is a rare malignant cerebral tumour in children. It has only a 1% 5-year survival rate, amongst other things because it is not possible to operate because the tumour is located in the brain stem.
› Verified 6 days ago
Dr. Alok Maheshwari, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-581-5400 Fax: 763-581-5401 | |
Hani Al Salti Al Krad, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5200 | |
Ethan Michael Fruechte, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Suite 200, Robbinsdale, MN 55422 Phone: 763-581-5400 Fax: 763-520-2099 | |
Matthew Nolan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3366 Oakdale Ave N Ste 401, Robbinsdale, MN 55422 Phone: 763-520-2940 | |
Jerrold Martin Stempel, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3366 Oakdale Ave N, Suite 315, Robbinsdale, MN 55422 Phone: 763-520-7900 Fax: 763-520-7989 | |
Chike Uchenna Anthony Obi, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-581-5400 Fax: 763-581-5401 | |
Dr. John Manion, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3435 West Broadway, Suite 1065, Robbinsdale, MN 55422 Phone: 763-520-1137 Fax: 763-520-1976 |